Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
汇报人: Catherine A. Shu
摘要号: 9006
时间：2022年6月4日 GMT+8 04:00
专场：口头报告
CLN-081用于EGFR外显子20插入突变NSCLC 患者的I/IIa 期研究
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases.
汇报人: Ernest Nadal
摘要号: 9010
时间：2022年6月7日GMT+8 05:42
专场：临床科学论坛
纳武利尤单抗+伊匹木单抗对比含铂化疗用于PS 2 或老年（≥ 70 岁）晚期NSCLC患者一线治疗的疗效：随机 III 期研究（Energy-GFPC 06-2015研究）。
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
汇报人: Jonathan W. Goldman
摘要号: 9013
海报号: 1
2022 年 6 月 7 日 GMT+8 02:15
专场：Poster Discussion Session（壁报讨论专场）
奥希替尼+necitumumab治疗EGFR突变NSCLC的疗效：ETCTN California Cancer Consortium I期研究结果。
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
汇报人: Astrid Paulus
摘要号: 9020
海报号: 8
时间：2022 年 6 月 7 日GMT+8 02:49
专场：壁报讨论
BFAST研究：恩曲替尼在ROS1阳性晚期/转移性 NSCLC患者中的疗效/安全性。
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).
汇报人: Solange Peters
摘要号: LBA9023
海报号: 11
时间：2022 年 6 月 7 日GMT+8 03:11
专场：壁报讨论
larotrectinib 在TRK阳性肺癌患者中的疗效和安全性更新结果。
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Three days of CIV rh-Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic, non-squamous non–small cell lung cancer (NSCLC): A open label, multicenter, phase II and cohort study (ENPOWER).
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
汇报人：Si-Yang Maggie Liu
摘要号: 9032
海报号: 20
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
免疫治疗新时代的无铂化疗方案：卡瑞利珠单抗+阿帕替尼+白蛋白紫杉醇治疗晚期非鳞状NSCLC (CAPAP-lung) 的 II 期研究。
Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.
汇报人：Likun Chen
摘要号：9041
海报号：29
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
洛拉替尼治疗ALK阳性初治晚期NSCLC患者后续治疗的PFS结果：来自III期研究的分析结果。
Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).
First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma.
汇报人：赵洪云
摘要号：9071
海报号：58
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
ALK/ROS1 酪氨酸激酶抑制剂 WX-0593 (iruplinalkib) 在ALK阳性、克唑替尼耐药晚期NSCLC患者中的 II 期试验。
A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non–small cell lung cancer.
汇报人：石远凯
摘要号：9073
海报号：60
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
阿来替尼联合贝伐珠单抗一线治疗ALK阳性晚期NSCLC患者的II期研究：ALEK-B研究
A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial.
汇报人: Oscar Gerardo Arrieta
摘要号: 9074
海报号: 61
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
SAF-189s治疗ALK阳性晚期NSCLC的结果：一项首次人体I/II期多中心研究。
SAF-189s in advanced, ALK-positive, non–small cell lung cancer: Results from a first-in-human phase 1/2, multicenter study.
Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort.
汇报人: Aurélie Swalduz
摘要号: 9082
海报号: 69
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
奈达铂+培美曲塞或顺铂+培美曲塞一线治疗EGFR/ALK 阴性晚期肺腺癌的疗效：一项多中心、开放标签、非劣效性、随机 III 期试验。
Nedaplatin plus pemetrexed or cisplatin plus pemetrexed as first-line chemotherapy for EGFR/ALK-negative advanced lung adenocarcinoma (NACA): A multicenter, open-label, non-inferiority, randomized, phase III trial.
Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.
Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFR-mutated non–small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
汇报人：Likun Chen
摘要号：9095
海报号：82
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
随机双盲 III 期试验 (AENEAS)：Aumolertinib治疗中枢神经系统（CNS）转移、EGFR 突变 NSCLC 患者的疗效。
Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).
Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study.
汇报人：Shiman Wu
摘要号：9098
海报号：85
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
伏美替尼对比吉非替尼在EGFR突变NSCLC患者中的CNS疗效：FURLONG 研究结果。
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.
汇报人：Gongyan Chen
摘要号：9101
海报号：88
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
Mefatinib一线治疗罕见 EGFR突变晚期NSCLC的疗效。
Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-na?ve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
汇报人: Tony S. K. Mok
摘要号: 9118
海报号: 104
时间：2022 年 6 月 6 日 GMT+8 21:00
专场：壁报展示
Tepotinib用于MET外显子14跳跃突变亚洲晚期 NSCLC 患者的疗效。
Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
